Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Current status of immunotherapy for the treatment of biliary tract cancer.

Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, Itoh K, Sasada T.

Hum Vaccin Immunother. 2013 May;9(5):1069-72. doi: 10.4161/hv.23844. Epub 2013 Feb 1. Review.

2.

Personalized peptide vaccine for treatment of advanced cancer.

Sasada T, Yamada A, Noguchi M, Itoh K.

Curr Med Chem. 2014;21(21):2332-45. Review.

PMID:
24524766
3.

Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.

Sasada T, Noguchi M, Yamada A, Itoh K.

Hum Vaccin Immunother. 2012 Sep;8(9):1309-13. doi: 10.4161/hv.20988. Epub 2012 Aug 16.

4.

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.

Noguchi M, Sasada T, Itoh K.

Cancer Immunol Immunother. 2013 May;62(5):919-29. doi: 10.1007/s00262-012-1379-1. Epub 2012 Nov 30. Review.

PMID:
23197273
5.

Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.

Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, Takeda K, Yamamoto M.

J Transl Med. 2014 Mar 7;12:61. doi: 10.1186/1479-5876-12-61.

6.

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

Antonarakis ES, Drake CG.

Curr Opin Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0. Review.

7.

[Personalized peptide vaccination].

Itoh K, Takahashi R, Yoshitomi M, Terasaki M, Noguchi M.

Nihon Rinsho. 2012 Dec;70(12):2118-23. Review. Japanese.

PMID:
23259383
8.

Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.

Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H.

Exp Ther Med. 2012 Mar;3(3):463-469. Epub 2011 Dec 20.

9.

Peptide vaccines for hepatocellular carcinoma.

Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T.

Hum Vaccin Immunother. 2013 Jan;9(1):210-2. doi: 10.4161/hv.22473.

10.

Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.

Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, Takeda K, Yamamoto M.

Clin Cancer Res. 2013 Apr 15;19(8):2224-31. doi: 10.1158/1078-0432.CCR-12-3592. Epub 2013 Mar 11.

11.

Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer.

Terazaki Y, Yoshiyama K, Matsueda S, Watanabe N, Kawahara A, Naito Y, Suekane S, Komatsu N, Ioji T, Yamada A, Mine T, Terasaki M, Itoh K, Takamori S, Sasada T.

Cancer Sci. 2012 Apr;103(4):638-44. doi: 10.1111/j.1349-7006.2012.02202.x. Epub 2012 Feb 13.

12.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
13.

[Current status and future perspective of peptide vaccine for biliary tract cancer].

Aruga A.

Nihon Rinsho. 2015 Mar;73 Suppl 3:823-6. Japanese. No abstract available.

PMID:
25857143
14.

Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.

Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlović S, Agur Z.

Cancer Res. 2012 May 1;72(9):2218-27. doi: 10.1158/0008-5472.CAN-11-4166. Epub 2012 Mar 15.

15.

Current developments with peptide-based human tumor vaccines.

Khazaie K, Bonertz A, Beckhove P.

Curr Opin Oncol. 2009 Nov;21(6):524-30. doi: 10.1097/CCO.0b013e328331a78e. Review.

PMID:
19770763
16.

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.

Noguchi M, Moriya F, Suekane S, Ohnishi R, Matsueda S, Sasada T, Yamada A, Itoh K.

BMC Cancer. 2013 Dec 30;13:613. doi: 10.1186/1471-2407-13-613.

17.

Prospect and progress of personalized peptide vaccinations for advanced cancers.

Sakamoto S, Noguchi M, Yamada A, Itoh K, Sasada T.

Expert Opin Biol Ther. 2016 May;16(5):689-98. doi: 10.1517/14712598.2016.1161752. Epub 2016 Mar 21.

PMID:
26938083
18.

Personalized peptide vaccination in patients with refractory non-small cell lung cancer.

Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T, Takamori S.

Int J Oncol. 2012 May;40(5):1492-500. doi: 10.3892/ijo.2012.1351. Epub 2012 Feb 1.

PMID:
22307435
19.

A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.

Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K.

BJU Int. 2011 Sep;108(6):831-8. doi: 10.1111/j.1464-410X.2010.09933.x. Epub 2010 Dec 16.

20.

Clinical peptide vaccination trials for leukemia patients.

Casalegno-Garduño R, Schmitt A, Schmitt M.

Expert Rev Vaccines. 2011 Jun;10(6):785-99. doi: 10.1586/erv.11.56. Review.

PMID:
21692700
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk